Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com..
BACKGROUND: There are limited data on outcomes of moderate to severe coronavirus disease 2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real-world setting. We sought to compare the effectiveness of standard of care (SOC) alone versus SOC plus remdesivir and dexamethasone.
METHODS: Two population-based nationwide cohorts of individuals hospitalized with COVID-19 during February through December 2020 were studied. Death within 30 days and need of mechanical ventilation (MV) were compared by inverse probability of treatment weighted (ITPW) logistic regression analysis and shown as odds ratio (OR) with 95% confidence interval (CI).
RESULTS: The 30-days mortality rate of 1694 individuals treated with remdesivir and dexamethasone in addition to SOC was 12.6% compared to 19.7% for 1053 individuals receiving SOC alone. This corresponded to a weighted OR of 30-day mortality of 0.47 (95% CI: .38-.57) for patients treated with remdesivir and dexamethasone compared to patients receiving SOC alone. Similarly, progression to MV was reduced (OR 0.36; 95% CI: .29-.46).
CONCLUSIONS: Treatment of moderate to severe COVID-19 during June through December that included remdesivir and dexamethasone was associated with reduced 30-day mortality and need of MV compared to treatment in February through May.
| Errataetall: |
ErratumIn: Clin Infect Dis. 2022 May 30;74(10):1889. - PMID 35460228 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 73(2021), 11 vom: 06. Dez., Seite 2031-2036 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
3QKI37EEHE |
|---|
| Anmerkungen: |
Date Completed 13.12.2021 Date Revised 07.12.2022 published: Print ErratumIn: Clin Infect Dis. 2022 May 30;74(10):1889. - PMID 35460228 Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciab536 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM326592547 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326592547 | ||
| 003 | DE-627 | ||
| 005 | 20231225194927.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciab536 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1088.xml |
| 035 | |a (DE-627)NLM326592547 | ||
| 035 | |a (NLM)34111274 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Benfield, Thomas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.12.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a ErratumIn: Clin Infect Dis. 2022 May 30;74(10):1889. - PMID 35460228 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: There are limited data on outcomes of moderate to severe coronavirus disease 2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real-world setting. We sought to compare the effectiveness of standard of care (SOC) alone versus SOC plus remdesivir and dexamethasone | ||
| 520 | |a METHODS: Two population-based nationwide cohorts of individuals hospitalized with COVID-19 during February through December 2020 were studied. Death within 30 days and need of mechanical ventilation (MV) were compared by inverse probability of treatment weighted (ITPW) logistic regression analysis and shown as odds ratio (OR) with 95% confidence interval (CI) | ||
| 520 | |a RESULTS: The 30-days mortality rate of 1694 individuals treated with remdesivir and dexamethasone in addition to SOC was 12.6% compared to 19.7% for 1053 individuals receiving SOC alone. This corresponded to a weighted OR of 30-day mortality of 0.47 (95% CI: .38-.57) for patients treated with remdesivir and dexamethasone compared to patients receiving SOC alone. Similarly, progression to MV was reduced (OR 0.36; 95% CI: .29-.46) | ||
| 520 | |a CONCLUSIONS: Treatment of moderate to severe COVID-19 during June through December that included remdesivir and dexamethasone was associated with reduced 30-day mortality and need of MV compared to treatment in February through May | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a dexamethasone | |
| 650 | 4 | |a pneumonia | |
| 650 | 4 | |a remdesivir | |
| 650 | 4 | |a survival | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a remdesivir |2 NLM | |
| 650 | 7 | |a 3QKI37EEHE |2 NLM | |
| 650 | 7 | |a Adenosine Monophosphate |2 NLM | |
| 650 | 7 | |a 415SHH325A |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 650 | 7 | |a Alanine |2 NLM | |
| 650 | 7 | |a OF5P57N2ZX |2 NLM | |
| 700 | 1 | |a Bodilsen, Jacob |e verfasserin |4 aut | |
| 700 | 1 | |a Brieghel, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Harboe, Zitta Barrella |e verfasserin |4 aut | |
| 700 | 1 | |a Helleberg, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Holm, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Israelsen, Simone Bastrup |e verfasserin |4 aut | |
| 700 | 1 | |a Jensen, Janne |e verfasserin |4 aut | |
| 700 | 1 | |a Jensen, Tomas Østergaard |e verfasserin |4 aut | |
| 700 | 1 | |a Johansen, Isik Somuncu |e verfasserin |4 aut | |
| 700 | 1 | |a Johnsen, Stine |e verfasserin |4 aut | |
| 700 | 1 | |a Lindegaard, Birgitte |e verfasserin |4 aut | |
| 700 | 1 | |a Lundgren, Jens |e verfasserin |4 aut | |
| 700 | 1 | |a Meyer, Christian Niels |e verfasserin |4 aut | |
| 700 | 1 | |a Mohey, Rajesh |e verfasserin |4 aut | |
| 700 | 1 | |a Pedersen, Lars Møller |e verfasserin |4 aut | |
| 700 | 1 | |a Nielsen, Henrik |e verfasserin |4 aut | |
| 700 | 1 | |a Nielsen, Stig Lønberg |e verfasserin |4 aut | |
| 700 | 1 | |a Obel, Niels |e verfasserin |4 aut | |
| 700 | 1 | |a Omland, Lars Haukali |e verfasserin |4 aut | |
| 700 | 1 | |a Podlekareva, Daria |e verfasserin |4 aut | |
| 700 | 1 | |a Poulsen, Birgitte Klindt |e verfasserin |4 aut | |
| 700 | 1 | |a Ravn, Pernille |e verfasserin |4 aut | |
| 700 | 1 | |a Sandholdt, Haakon |e verfasserin |4 aut | |
| 700 | 1 | |a Starling, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Storgaard, Merete |e verfasserin |4 aut | |
| 700 | 1 | |a Søborg, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Søgaard, Ole Schmeltz |e verfasserin |4 aut | |
| 700 | 1 | |a Tranborg, Torben |e verfasserin |4 aut | |
| 700 | 1 | |a Wiese, Lothar |e verfasserin |4 aut | |
| 700 | 1 | |a Christensen, Hanne Rolighed |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 73(2021), 11 vom: 06. Dez., Seite 2031-2036 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2021 |g number:11 |g day:06 |g month:12 |g pages:2031-2036 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciab536 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2021 |e 11 |b 06 |c 12 |h 2031-2036 | ||